• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Kura Oncology (KURA)

Common Shares
Sell: $10.30|Buy: $10.39|Change: 0.17 (1.66%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.

Address

3033 Science Park Road
Suite 220
San Diego
CA
USA
92121

Telephone

+1 858 500-8800

Website

https://www.kuraoncology.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Kura Oncology Inc Third Quarter Earnings Conference Call for 20262026-11-04T08:00:00
Kura Oncology Inc Third Quarter Earnings Results for 20262026-11-04T00:00:00
Kura Oncology Inc Second Quarter Earnings Conference Call for 20262026-08-07T16:30:00
Kura Oncology Inc Second Quarter Earnings Results for 20262026-08-07T00:00:00
Kura Oncology Inc Annual General Meeting for 20262026-06-05T08:30:00
Kura Oncology Inc First Quarter Earnings Conference Call for 20262026-05-01T16:30:00
Kura Oncology Inc First Quarter Earnings Results for 20262026-05-01T00:00:00
Kura Oncology Inc Annual Report for 20252026-02-27T00:00:00
Kura Oncology Inc Fourth Quarter Earnings Conference Call for 20252026-02-26T16:30:00
Kura Oncology Inc Fourth Quarter Earnings Results for 20252026-02-26T00:00:00

Previous key dates

NameKey Date
KURA ONCOLOGY 67th American Society of Hematology2025-12-08T12:30:00
Jefferies Global Healthcare Conference2025-11-19T10:30:00
Kura Oncology Inc Third Quarter Earnings Conference Call for 20252025-11-04T08:00:00
Kura Oncology Inc Third Quarter Earnings Results for 20252025-11-04T00:00:00
Discussion of Clinical Data Presented at 2025 ESMO Congress, Including First Clinical Data from KO-2806, Kura’s Next-Generation FTI2025-10-18T13:30:00
FTI Preclinical Program Review: Synergistic Combinations with Targeted Therapies2025-09-16T16:30:00
Morgan Stanley 23rd Annual Global Healthcare Conference2025-09-10T13:50:00
H.C. Wainwright 27th Annual Global Investment Conference2025-09-08T13:00:00
Cantor Global Health Conference2025-09-04T08:35:00
Kura Oncology Inc Second Quarter Earnings Conference Call for 20252025-08-07T16:30:00
Kura Oncology Inc Second Quarter Earnings Results for 20252025-08-07T00:00:00
Kura Oncology EHA Virtual Investor Event 20252025-06-18T16:30:00
Goldman Sachs Annual Global Healthcare Conference2025-06-10T11:20:00
Kura Oncology Inc Annual General Meeting for 20252025-06-05T08:30:00
Jefferies Global Healthcare Conference2025-06-04T14:35:00
TD Cowen’s 6th Annual Oncology Innovation Summit2025-05-27T09:00:00
Kura Oncology Inc First Quarter Earnings Conference Call for 20252025-05-01T16:30:00
Kura Oncology Inc First Quarter Earnings Result for 20252025-05-01T00:00:00
Stifel 2025 Virtual Targeted Oncology Forum2025-04-08T10:30:00
Leerink Partners Global Biopharma Conference2025-03-12T08:00:00
Barclays Global Healthcare Conference2025-03-11T09:30:00
TD Cowen Health Care Conference2025-03-04T14:30:00
Kura Oncology Inc Annual Report for 20242025-02-28T00:00:00
Kura Oncology Inc Fourth Quarter Earnings Conference Call for 20242025-02-26T16:30:00
Kura Oncology Inc Fourth Quarter Earnings Result for 20242025-02-26T00:00:00
Kura Oncology Virtual Investor Event2025-02-05T16:30:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.